Thursday, July 24th11.8°C
21452
21901

Valeant continues its efforts to buy Allergan by initiating shareholder 'referendum'

MONTREAL - Valeant Pharmaceuticals is stepping up its fight for Botox maker Allergan, saying it plans to initiate a "shareholder referendum" of investors and may pursue a special meeting to remove some or all of the U.S. company's board of directors.

The Quebec-based company said Thursday that the referendum would determine if Allergan's shareholders want its board to negotiate with Valeant at the same time as it pursues alternatives to Valeant's hostile takeover bid.

"We expect that this referendum will send a clear message to the Allergan board and to us that Allergan's shareholders strongly support negotiations between our two companies in parallel with their other efforts," chief financial officer Howard Schiller told financial analysts.

The California-based company has refused to enter into negotiations to discuss Valeant's proposed US$48-billion cash and share offer. It responded by adopting a "poison pill" defence that will allow its board time to consider alternatives and potentially block the bid.

Two weeks ago, Valeant offered US$48.30 in cash and 0.83 of a Valeant share for each share of Allergan (NYSE:AGN). The offer would be worth about US$159 a share at Valeant's trading price Thursday or almost US$48 billion. Allergan Inc. stockholders would own 43 per cent of the combined company.

During a conference call Thursday to discuss its first-quarter results, Valeant said it is "very committed" to getting the deal done to create "an unrivalled platform for growth and value creation."

Schiller said several meetings with Allergan shareholders produced "overwhelmingly positive" feedback to its offer.

He said several themes emerged from the meetings, including that the deal will give shareholders value, there's little push back to Valeant's claim that Allergan's research and development spending is too high and cost structure excessive, and that the two sides should start negotiations as soon as possible.

Chief executive Michael Pearson also said Valeant's outlook on combining the companies was reinforced in talking to Allergan's shareholders.

"It's clear that they really see the compelling nature of this transaction and we have strong, strong support to get this deal done," he said.

In the meanwhile, Valeant and its partner Pershing Square will request a shareholder list from Allergan, which it says the company is required to provide under Delaware law.

Valeant anticipates the proposed Allergan deal will result in more than US$2.7 billion in annual cost savings, 80 per cent of which would be achieved in the first six months. It says last year's acquisition of eyecare company Bausch & Lomb is an example for removing layers of management while driving higher sales.

Meanwhile, Valeant reported Thursday that its revenues jumped 77 per cent to US$1.9 billion, while its profit adjusted for one-time items increased 48 per cent to US$599.7 million from US$405.2 million a year ago. That translated into US$1.76 per share, up from US$1.30 a year earlier.

Valeant (TSX:VRX) was expected to earn $1.72 per share in adjusted profits on US$1.97 billion of revenues, according to analysts polled by Thomson Reuters.

Including one-time items, it lost US$22.6 million or seven cents per share for the period ended March 31. That compared to a loss of US$27.5 million or nine cents per share in the first quarter of 2013.

Valeant said the loss includes restructuring, integration and other charges of $135 million primarily related to Bausch & Lomb purchase.

Neil Maruoka of Canaccord Genuity said with Valeant and Allergan reporting strong quarters, "the table is now set for a heightened battle" between the two companies.

"While Allergan's board has stated that it will carefully review Valeant's US$50 billion bid, we believe that it is likely considering other options including smaller acquisitions that would allow a tax inversion," he wrote in a report.

The analyst said there is "a good chance" that Valeant's bid will be successful, but will likely have to boost its cash offer.

Maruoka described Valeant's first-quarter results as "solid" despite the slight revenue miss.

Valeant has said its goal is to be one the world's top five pharmaceutical companies, with a market value of roughly $150 billion.

It was originally based in California and merged with Canada's Biovail in 2010, headquartered in Mississauga, Ont. Valeant moved its global headquarters to Laval, near Montreal, in 2012.

On the Toronto Stock Exchange, Valeant's shares gained 92 cents at C$145.98, and traded up 99 cents at US$134.34 in New York.

Follow @RossMarowits on Twitter.

The Canadian Press


Read more Business News

22315


Recent Trending




Today's Market
S&P TSX15412.03+17.65
S&P CDNX1010.06-2.17
DJIA17103.9417.31
Nasdaq4480.186+6.489
S&P 5001990.13+3.12
CDN Dollar0.9311-0.0013
Gold1297.50-7.00
Oil104.30-0.29
Lumber325.50-7.90
Natural Gas3.841+0.079

 
Okanagan Companies
Pacific Safety0.200.00
Knighthawk0.01-0.005
QHR Technologies Inc1.16+0.01
Cantex0.08+0.02
Anavex Life Sciences0.287-0.038
Metalex Ventures0.075+0.005
Russel Metals35.74+0.09
Copper Mountain Mining2.815+0.055
Colorado Resources0.21-0.005
ReliaBrand Inc0.10+0.019
Sunrise Resources Ltd0.025-0.005
Mission Ready Services0.19+0.01

 





FEATURED Property
14436168856 Hampshire Crescent
10043325 bedrooms
$189,900
more details
image2image2image2
Click here to feature your property
Please wait... loading


Geopolitical tensions rattle markets

The Big Picture Geopolitical tensions rattle markets The spectre of rising geopolitical tensions in Ukraine and Gaza cast a shadow over an otherwise positive week in the markets. News that a passenger...


Labour shortage in BC

The mainstream media are finally waking up to something unusual in British Columbia – a labour shortage. If the experience of Alberta is a guide to our own future, the highly skilled labour will...


Learn to delegate effectively

Photo: ContributedI have the pleasure of witnessing people delegate tasks quite often. Sometimes with tremendous success and sometimes with disastrous consequences. I have chaired a lot of committees...

_








Member of BC Press Council


22097